Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, or stroke.

A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that the ...

Please provide your email address to receive an email when new articles are posted on . Dulaglutide, semaglutide and tirzepatide had similar GI safety profiles. An increased risk for GI adverse events ...

Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial, ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...